Pharmalot… Pharmalittle… The Weekend Nears

And so, another working week is drawing to a close. Actually, we are rolling in the sidewalks momentarily, since this is an official day off here at the Pharmalot corporate campus. The schoolhouses are closed and we promised the short people we would spend some time with them. So we have arranged a few items for you and then will be on our way. As for you, we hope you do something fun, interesting or worthwhile – or all of the above – this weekend. After all, life is short. Might as well enjoy. And while you do, please be safe. See you soon… Feds Probe J&J Over Hip Implant Marketing (Associated Press) FDA Approves Roche Drug For Late-Stage Breast Cancer (Reuters) In US, Flu Vaccine Worked In Half Of Those Innoculated (Reuters) Vivus Diet Pill Rejected Again By EU Regulators (Pharma Times) Florida Legislature Debates Biosimilars Bill (The Ledger) J&J Toxicologist Says Metal From Hip Recalls Is Harmless (Bloomberg News) European API Distributors Face New Costs Under GDP Proposals (InPharma Technologist) Pricey Aegerion Cholesterol Pill Worries Insurers (Philadelphia Inquirer) Elan Plans $1B Share Buyback (Reuters) Health IT Start Up Can Predict Patient Adherence (MedCity News) Genentech Tax Appeal Hurts Oregon Town (The Oregonian)
Source: Pharmalot - Category: Pharma Commentators Authors: Tags: Uncategorized Active Pharmaceutical Ingredients API Breast Cancer Dan Vasella Diet Pills Elan Flu Genentech Influenza JJ Johnson & Johnson Novartis Obesity Patient Adherence Roche Vaccines Vivus Source Type: blogs